RxDoctor Payments Data

Kevin Cunningham, DO

Family Medicine · Eastland, TXNPI 1114054673

Payments from drug & device makers

$663in general payments, 2019–2025

Across 36 payments — averaging $18.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Corcept Therapeutics$92
  • AstraZeneca$89
  • Astellas Pharma US Inc$58
  • Novartis$58
  • AbbVie$51
  • Novo Nordisk$50
  • plus $266 from 14 others

What the payments were for

  • Food & beverage$663100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$663 in reported general payments places this provider in the 55th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$116,843
Medicare patients
290
Services billed
7,252

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin66$79,943
EliquisApixaban60$55,616
RybelsusSemaglutide34$47,140
EntrestoSacubitril/Valsartan28$36,335
FarxigaDapagliflozin Propanediol31$23,778
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog49$23,321
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$21,765
XareltoRivaroxaban19$20,302
OzempicSemaglutide21$19,922
MyrbetriqMirabegron32$14,299
GemtesaVibegron18$9,543
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog14$8,195
BrilintaTicagrelor11$5,235
SymbicortBudesonide/Formoterol Fumarate20$4,871
Lantus SolostarInsulin Glargine,hum.Rec.Anlog31$4,271

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$15$79,94366 claims
Novo NordiskRybelsus, Ozempic$50$67,06155 claims
NovartisEntresto$58$36,33528 claims
AstraZenecaFarxiga, Brilinta, Symbicort$89$33,88562 claims
GSKTrelegy Ellipta$19$21,76526 claims
Johnson & JohnsonXarelto$34$20,30219 claims
Astellas Pharma US IncMyrbetriq$58$14,29932 claims
Sumitomo Pharma America, Inc.Gemtesa$18$9,54318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Eastland

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →